Investing.com – Company INVO Bioscience (NASDAQ: ) Q3 report beat analysts’ estimates with lower-than-expected earnings, according to data released Monday.
INVO Bioscience’s earnings per share (EPS) were $-0.700 on revenue of $970K. The analyst consensus compiled by Investing.com for the upcoming forecast was previously seen at $-2.200 per share on revenue of $1.82M.
INVO Bioscience shares added 4.35% to $1.680 in after-hours trading. After the news of earnings report
Apart from INVO Bioscience, there are other companies. Markets report this month’s earnings in the healthcare sector of the NASDAQ Stock Exchange
Eli Lilly previously estimated Q3 earnings at $0.1 per share on revenue of $9.5B, and $-0.2 on revenue of $8.97B.
Novo Nordisk ADR’s latest reported performance beat analyst estimates. Q3 earnings came in at $5 per share on revenue of $58.73B, compared to consensus analyst estimates. Investing.com expects EPS to be around $0.6751 based on revenue of $8.16B.
Follow the latest developments in company profits with the Investing.com Earnings Calendar
“Avid gamer. Social media geek. Proud troublemaker. Thinker. Travel fan. Problem solver.”